Ahead of its planned spinoff from GE the first week of January
2023, GE Healthcare reveals over 40 solutions that aim to improve
patient outcomes and increase healthcare efficiency at the
Radiological Society of North America’s (RSNA) 2022 Annual
Meeting.
Drawing on more than 100 years of history as a trusted medical
technology innovator1, GE Healthcare is closely connected with
healthcare systems globally. Knowing the industry is under immense
pressure, the company is proud to introduce its latest innovations
to help solve for the biggest challenges in healthcare today –
including rising cost pressures, increasing staff shortages,
mounting expectations to deliver outcomes, and more – while also
aiming to improve healthcare in the future.
“With an unparalleled combination of technology solutions and
clinical understanding, we have a unique ability to help solve
industry challenges by delivering clinical and operational insights
through integrated data, analytics and devices,” said Peter
Arduini, CEO of GE HealthCare. “A new era is coming for GE
Healthcare and with it, we hope to help healthcare transform as a
whole by advancing precision diagnostics, improving capacity and
efficiency, and increasing patient access.”
Connecting healthcare for better patient outcomes
GE Healthcare aims to erase segmented care and fill in the gaps
in healthcare systems’ workflows to increase access and improve
outcomes for patients across the care continuum - all while
achieving greater connectivity, resilience, and agility to enhance
the clinician experience.
GE Healthcare delivers connected care across care pathways with
leading imaging, digital and patient monitoring capabilities that
help improve patient care throughout each individual’s journey.
To help clinicians deliver care that’s more personal and
precise, while also enabling greater healthcare system
efficiencies, GE Healthcare offers several game-changing
solutions:
- SIGNA Experience: A platform of four inventive
components, which are SIGNA One - a new anticipatory user
interface with virtually no learning curve, AIR Recon DL,
AIR Coils and automated workflow solutions, that
leverage AI and deep learning to enhance workflow productivity,
drive clinical efficiency and bring automation and simplification,
to ensure the smoothest scanning experience in magnetic resonance
(MR) imaging.
- SIGNA Victor: The newest 1.5T 60cm system designed to
address today’s most pressing and unprecedented industry challenges
such as sharp increase in MR examinations driven by the stalled
pandemic demand, surging power and commodity costs, and labor
shortage and staff burnout. With SIGNA Experience being integrated
for the first time in this 1.5T segment, the system offers all the
benefits of the platform, in addition to efficient helium and power
consumption that can support higher patient throughput and lower
costs which leads to faster ROI.
- Revolution Apex platform with Effortless Workflow: An
industry first2 Computed Tomography (CT) platform with built-in
scalability for onsite CT detector upgrades – all without replacing
the gantry3. Offering uncompromised clinical capabilities, the new
Revolution Apex platform offers the world’s fastest gantry speed3,4
and helps radiology departments stay ahead of the technology curve
with a modular design that offers a seamless path to continuous
hardware and software scalability and upgradability that can extend
the lives of CT systems into the future3 . This platform – along
with select other GE Healthcare CT systems – are complete with
Effortless Workflow, which utilizes AI technologies to automate
nearly every step in existing workflows – from pre-scan to
post-scan.
- CT Motion: A GE Healthcare branded multi-dose
syringeless injector that delivers iodinated contrast media for
Computed Tomography (CT) imaging procedures, reduces procedure
setup time and increases patient throughput while helping to
optimize patient dosing and reduce wasted contrast media.
- Intelligent workload management solution for PACS:
Provided through Quantum Imaging & Therapeutic Associates’
Helix Radiology Performance Suite, which operates on predictive
analytics, the intelligent workload management solution can help to
optimize radiologists’ workflow across an entire enterprise to
improve radiologist’s productivity and reduce burnout.
- Imaging 360 for Operations: An ecosystem of applications
designed for core imaging operations functions such as protocoling,
staffing, analytics, and scheduling.
- Quality Care Suite 2.0: A collection of AI algorithms
that enable the delivery of high quality, radiologist-ready images
for every patient – including pediatric patients, a first for GE
Healthcare X-ray AI.
- Definium 656: The latest generation of the overhead tube
suspension (OTS) system features the highest levels of
motorization, automation, assistive intelligence and advanced
applications with the fastest movement and highest weight capacity
in GE Healthcare’s fixed X-ray portfolio.
- LOGIQ Fortis: An all-in-one, high-performing ultrasound
solution that can easily be scaled to fit the specific needs of
every clinician. Sound Architecture combines XDclear™ transducers,
cSound™ Imageformer and new, advanced Speckle Reduction Imaging
(SRI) technology to increase processing power that delivers
enhanced data throughput, ultimately providing exceptional image
quality, clarity and clinical confidence across a wide range of
clinical applications.
- Vivid E95 Ultra Edition: A premium 4D cardiovascular
ultrasound system, designed to provide uncompromised image quality,
advanced visualization capabilities, and easy measurements, while
helping reduce tedious tasks and inter-observer variability. It
also features the world’s first mini 4D TEE probe, suitable for a
broad range of paediatric interventional cardiology procedures, and
potentially helping eliminate the need for general anaesthesia in
adult patients.
Strategic collaborations in precision oncology
As an open-architecture, multi-dimensional ecosystem, GE
Healthcare helps connect teams, multimodal data, and decisions at
every step – from discovery to diagnosis to treatment and
monitoring – with intelligently efficient innovations designed to
help clinicians deliver precise, personalized care.
In concert with collaborators in adjacent fields who are
well-versed in their disciplines, GE Healthcare is proud to work
together with some of healthcare’s leading innovators across care
pathways, including oncology.
Some of GE Healthcare’s recent collaborations in cancer care
include:
- Accuray, to expand access to personalized medicine,
bringing together precision diagnostic tools that enable earlier
diagnosis with innovative delivery capabilities to provide
patient-adapted treatments.
- Elekta, to provide healthcare providers a comprehensive
offering across imaging and treatment for cancer patients requiring
radiation therapy.
- Optellum, to help advance early detection, precision
diagnosis and the treatment of lung cancer.
- RaySearch, to improve radiation oncology treatment
planning.
- SOPHiA Genetics, to advance cancer care with the goal of
better targeting and matching treatments to each patient’s genomic
profile and cancer type.
- Tribun Health, to focus on making digital pathology
images and results an integrated part of the imaging patient
record, while also helping to foster collaboration among
pathologists and clinicians through availability of data in a
consolidated location.
Ushering in a new era of healthcare with innovative
diagnostics
Looking towards the future, GE Healthcare is uniquely positioned
to advance precision care through theranostics.
Where most medical therapies are designed with the ‘average’
patient in mind, theranostics brings together diagnostics and
therapeutics to provide a more targeted and personalized treatment
than ever before5. Clinicians and patients are especially seeing
success with theranostics in prostate cancer – a highly manageable
disease, but one that is difficult to treat when diagnosed at a
late stage, claiming more than 1.4 million lives annually6 .
To advance this growing field and help clinicians improve
patient outcomes, GE Healthcare is proud to be the only partner
with solutions covering the breadth of steps required from
discovery to diagnosis to treatment.
“As the only partner with solutions spanning from pharmaceutical
diagnostics, cyclotrons, chemistry synthesis, PET/CT, PET/MR,
SPECT/CT, and advanced oncology and digital solutions, we cover the
breadth of steps from discovery to diagnosis to treatment,” said
Jamie McCoy, General Manager, Theranostics and Radiotherapeutics,
GE Healthcare. “Ultimately, we hope that by advancing the
integration of diagnostics and therapeutics, we can help usher in a
new era in healthcare that enables clinicians to provide more
targeted and personalized therapies for improved patient outcomes
than ever before.”
This includes several standout products to enable greater
adoption of theranostics in practice:
- A new Solid Target Platform for GE Healthcare’s PETtrace
cyclotron – in combination with its FASTlab 2 New Edition platform
– can produce 100x the amount of Gallium for radioisotope
production compared to a common generator for increased
theranostics capabilities and access in prostate cancer patient
care7.
- Omni Legend is an all-new, all-digital PET/CT platform
that enables clinicians to image short life tracers and reach new
levels of sensitivity and detectability for clear images and
greater clinical information across more oncology, cardiology, and
neurology procedure types than ever before. Using GE Healthcare’s
proven deep learning expertise for image acquisition and
reconstruction, the system boasts the highest sensitivity per cm in
the market5 and images Gallium-68 for diagnosis, staging, or
restaging of disease.
- StarGuide, GE Healthcare’s dynamic 3D SPECT/CT system,
delivers new digital focus detector technology that efficiently
enables treatment monitoring – including Lutetium-177 for prostate
cancer – and offers Xeleris V with AI solutions such as
Q.Thera AI8 for dose personalization.
For more information on GE Healthcare and its innovative
solutions at RSNA, visit Booth 7324 or the RSNA 2022 events
page.
About GE Healthcare:
GE Healthcare is the $17.7 billion healthcare business of GE
(NYSE: GE). As a leading global medical technology, pharmaceutical
diagnostics and digital solutions innovator, GE Healthcare enables
clinicians to make faster, more informed decisions through
intelligent devices, data analytics, applications and services,
supported by its Edison intelligence platform. With over 100 years
of healthcare industry experience and around 48,000 employees
globally, the company operates at the center of an ecosystem
working toward precision health, digitizing healthcare, helping
drive productivity and improve outcomes for patients, providers,
health systems and researchers around the world.
Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights
for the latest news, or visit our website www.gehealthcare.com for
more information.
_______________
1
https://www.gehealthcare.com/about/about-ge-healthcare-systems#what-we-do
2 GE Healthcare data on file. 3 Scalability and upgradability are
subject to the availability and compatibility of new capabilities
and products. 4 0.23sec and 19.5msec are 510k pending and not
available for sales in all countries. 19.5msec effective temporal
resolution is achieved by a 6x improvement of motion-blur reduction
while maintaining high spatial resolution as demonstrated in
cardiac phantom testing. The reduction in motion artifacts is
comparable to a 0.039 equivalent gantry rotation speed with
effective temporal resolution of 19.5 msec, as demonstrated in
mechanical and mathematical phantom testing. 5 Pharmacy Management
System Market - Growth, Trends, Covid-19 Impact, And Forecasts
(2022 - 2027). Mordor Intelligence. Accessed November 17, 2022.
https://www.mordorintelligence.com/industry-reports/pharmacy-management-system-market#:~:text=Where%20most%20medical%20therapies%20are,personalized%20therapy%20than%20ever%20before
6 “Cancer.” World Health Organization. Feb 3, 2022. Accessed Jun 1,
2022. https://www.who.int/news-room/fact-sheets/detail/cancer 7
Svedjehed et al. “Demystifying solid targets: Simple and rapid
distribution-scale production of [68Ga]GaCl3 and [68Ga]Ga-PSMA-11.”
Nuclear Medicine and Biology. Volumes 104–105, January–February
2022, Pages 1-10. https://doi.org/10.1016/j.nucmedbio.2021.10.002 8
CE marked. 510(k) pending in the U.S. Not for sale in the U.S. Not
cleared or approved by the U.S. FDA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221127005061/en/
Kyerstin Hill External Affairs, GE Healthcare
Kyerstin.hill@ge.com 708-738-7741
General Electric (NYSE:GE)
Historical Stock Chart
From Mar 2023 to Mar 2023
General Electric (NYSE:GE)
Historical Stock Chart
From Mar 2022 to Mar 2023